Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Oct 5, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at two different surgical techniques for treating benign prostatic hyperplasia (BPH), a condition that affects many men over 40 and can cause difficulty with urination. The study specifically compares a method that aims to preserve the ability to ejaculate with a traditional method that often leads to ejaculation problems. Researchers believe that by using a modified technique, they can help men maintain their sexual function while still relieving their urinary symptoms.

To be eligible for this trial, participants must be men over 40 years old who have been diagnosed with BPH and have certain urinary issues as measured by specific tests. They should also be willing to attend follow-up visits and provide consent to participate. If you join the study, you can expect to receive one of the two surgical treatments and will be monitored for your recovery and functional outcomes. This trial is important because it seeks to improve the quality of life for men facing BPH by minimizing side effects related to sexual function.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Man over 40 years old
• • Indication of surgical management for BPH
• • Prostate volume ≥30 cc and ≤150 cc as evaluated by ultrasonography ( or an MRI if available)
• • IPSS score ≥12
• • Qmax ≤15 ml/s
• • Affiliated to French national social security system
• • wish and be able to comply with planned visits
• • Able to express his consent
• • Signed informed consent form
• Exclusion Criteria:
• • Unwillingness to accept the treatment
• • No pre-operative ejaculation or sexuality
• • Neurological pathology responsible for micturition disorders
• • History of prostatic surgery
• • Stenosis of the urethra symptomatic
• • History of prostate cancer
• • History of radiotherapy or pelvic surgery
• • Patient refusing the principle of partial surgery
• • Life expectancy \<3 years
• • Inability to understand the informed consent document, to give consent voluntarily or to complete the study tasks.
• • Participation in another clinical study involving an investigational product within 1 month before study entry.